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Summary
It has been established that secondary hyperparathyroidism
(SHPT) represents a long-term complicance of chronic renal
failure (CRF) associated to diffuse or nodular hyperplasia of
parathyroid glands. The molecular mechanisms underlying
both hyperactivity and proliferation rate of parathyroid cells in
uremic patients have not yet been elucidated. A decreased sen-
sitivity to vitamin D feedback is considered one of the causes
accounting for parathyroid hyperplasia in CRF. Thus, we inves-
tigated the possible role that VDR gene may play in the devel-
opment of parathyroid tumors in three female patients exhibit-
ing refractory SHPT. We detected in one parathyroid nodular le-
sion from one patient a loss of heterozygosity within the VDR
locus with acquisition of the haplotype previously described to
segregate with lower bone mass values and lower intestinal cal-
cium absorption efficiency in Italian postmenopausal women.
These findings suggest that qualitative/ quantitative deficiency
of VDR physiological activity may have a role in the pathogene-
sis of secondary hyperparathyroidism in uremic patients.
KEY WORDS: parathyroid tumorigenesis, vitamin D receptor, genetic poly -
morphisms.
Introduction
As in other human complex disorders, genetic association stud-
ies may provide data that could be helpful in precocious detec-
tion of subjects at risk to develop parathyroid hormone deregu-
lation in presence, or not, of specific environmental factors.
Many recent reports are focusing on the existence of a possible
segregation between specific VDR gene polymorphisms and
parathyroid proliferative disorders outcome in different ethnical
groups (1-3). Such polymorphic sites can be useful also to in-
vestigate the role that the V D R gene may play in the pathogen-
esis of parathyroid outgrowth at tumoral level, unraveling the
association between a particular V D R gene haplotype and calci-
um homeostasis disorder. VDR expression has been shown to
be negatively correlated with parathyroid gland potential in he-
modialysis patients affected by secondary hyperparathyroidism
(SHPT). A previous immunohistochemical study in parathyroid
glands from uremic patients demonstrated a lower VDR density
in parathyroid cells in nodular hyperplasia when compared to
the diffuse lesions, suggesting a direct involvement of VDR in
the pathogenesis of refractory SHPT (4). More recently, Yano et
al. demonstrated a decreased expression of both calcium sens-
ing receptor (CaSR) and VDR in parathyroid glands from pa-
tients affected by uremic SHPT (5) suggesting an important role
for both the receptor proteins in the increased proliferative activ-
ity of parathyroid cells in these individuals. Moreover, associa-
tion studies investigating intron 8 (B /b and A / a alleles) and exon
9 (T / t alleles) of VDR gene polymorphisms, detected by BsmI,
ApaI and TaqI endonucleases respectively, showed a higher
prevalence of b a T haplotype in Swedish patients affected by
primary hyperparathyroidism (PHPT) (1-2). These results were
not confirmed in a Japanese population study (3), even if an as-
sociation study on a Spanish postmenopausal women popula-
tion with PHPT failed to demonstrate a role of BsmI VDR poly-
morphism in the pathogenesis of parathyroid adenomas (6).
However, genetic differences among ethnical groups could ac-
count for such discrepancies. The b a T haplotype could be relat-
ed to an altered expression of V D R gene with reduction of spe-
cific mRNA levels (7). The possible influence of VDR polymor-
phisms on quantitative/qualitative defects of its own mRNA has
not been defined. Several clonality studies demonstrated the
existence of monoclonal lesions in parathyroid from uremic pa-
tients both by X-chromosome inactivation pattern and loss of
heterozygosity (LOH) at several different autosomal loci (8-11),
indicating the existence of a high degree of genetic heterogene-
ity. A report on LOH analysis in parathyroid glands from patients
with refractory SHPT seemed to confirm these data with some
parathyroid nodules exhibiting LOH at different loci, including
loci at 12q12-14, the region harboring the V D R gene (12). Con-
sidering all these data we decided to investigate the possible
role of the V D R gene in the pathogenesis of refractory SHPT in
uremic patients.
Patients and methods
After obtainment of a signed informed consent, approved by
the Local Ethical Board, from each participating patient, DNA
samples from seven hyperplastic parathyroid glands (2 diffuse
and 3 nodular forms) from three female patients with refractory
SHPT (3 from patient I, 2 from patient II and 2 from patient III)
(age range 53- 56 years) and from matched peripheral blood
were analyzed. Selective PCR amplification of a 740 bp and a
265 bp DNA fragments, using a forward primer in intron 8 and
a reverse primer in exon 9 for the 740 bp fragment (11-12) and
primers on both sides flanking exon 1 of VDR gene (13) for the
second fragment, followed by restriction fragment length poly-
morphism (RFLP) analysis with Apa I, Taq I (intron 8/exon 9)
and FokI (exon 1) were performed (14) (Figure 1). The RFLPs
were coded as Aa (ApaI), Tt (TaqI) and Ff (FokI), upper case
letter indicates the absence and lowercase the presence or the
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restriction site. The patients resulted to be heterozygous both
in constitutive and parathyroid tissue DNA for all RFLPs analy-
sis (Aa, Tt and Ff), but patient I homozygous for ApaI site (AA).
In order to define the size of the lost region we performed also
the VDR poly-A microsatellite analysis at 3’UTR (15) (Figure
1). All patients resulted to be informative (data not shown).
Results
Only one parathyroid gland with a nodular pattern of growth
from patient III, constitutively genotyped as Aa/Tt, exhibited the
loss of “T” and “a” allele (Figure 2A and 2B), while both the cor-
responding FokI (Figure 3) and VDR poly-A polymorphisms
were informative and the DNA retained. Thus, this gland ac-
quired the “hemizygous” haplotype At with an intragenic dele-
tion included between the FokI site on exon 2 and the VDR
poly-A at the 3’UTR.
Discussion
Present result supports the theory of genetic heterogeneity at the
molecular basis of SHPT, representing the first evidence of “intra-
genic” chromosomal deletion at the VDR locus. A previous report
excluded tumor-specific deletion, insertions or point mutations in
the VDR gene in 37 parathyroid tumors from uremic patients by
multiple independent methods (16). We consider our result to be
an occasional, if not unique, molecular event that probably do not
represent a frequent promoting mechanism in the tumorigenesis
of such parathyroid lesions. In fact, a similar nodular pattern was
also exhibited by the glands without VDR intragenic deletion.
Thus, we confirm that it is unlikely that the VDR locus may play
as a tumor suppressor gene in severe secondary or tertiary hy-
perparathyroidism tumorigenesis. In a previous association study
on an Italian postmenopausal women population, it has been re-
ported the existence of a strong correlation between the homozy-
gous genotype AA/tt, lower bone mass values and lower intesti-
nal calcium absorption efficiency, suggesting the existence of a
qualitative/quantitative deficiency of VDR physiological activity
(17). The acquisition of such defective molecular mechanism in
uremic parathyroid glands could also account for the observed re-
fractory behavior, may be due to a decreased sensitivity of
parathyroid cells to vitamin D regulation with different pharmaco-
logical response to vitamin D treatment and consequent develop-
ment of a parathyroid clonal expansion. Efforts should be ad-
dressed to assess the VDR function in a larger number of uremic
parathyroid glands in order to confirm our data.
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Figure 1 - Genomic organization and described polymorphisms at the
VDR gene. Grey boxes represent untranslated regions (UTR) and white
boxes (from Ex 2 to Ex 9) represent the coding regions. The specific re-
striction endonucleases and corresponding detected alleles (within
brackets) are given.
Figure 2 - A) TaqI and B) ApaI restriction analysis of the 740 bp PCR
product of VDR gene in parathyroid glands (P) of patient II and III and
the matched constitutive DNA (C). Two separate nodular lesions from
patient II and one nodular lesion from patient III (duplicated) are here
described. The size of detected alleles (bp) is reported on the left of the
agarose gel picture. Parathyroid from patient III exhibited loss of “T” al-
lele (495 bp) in A and of “a” allele (520+220 bp) in B.
Figure 3 - FokI restriction analysis of the 265 bp PCR product of the
same samples described in Figure 2 of patients II and III. All the
parathyroid glands retained the DNA.
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